| HOME >> MEDICINE >> TECHNOLOGY |
(10.5)6.7Trade accounts payable
(3.8)(27.5)Other liabilities
18.944.0 Other, net
0.7(2.3)Net Cash Provided by Operating Activities
87.06.1Cash Flow From Investing Activities: Capital expenditures (including instruments placed with or leased to customers)
(67.3)(62.2) Purchases of intangibles and other investments
(3.6)(2.5) Proceeds from disposition of businesses and assets
3.113.3Net Cash Used in Investing Activities
(67.8)(51.4)Cash Flow From Financing Activities: Other borrowings, net
27.50.4 Excess tax benefit from stock-based compensation arrangements
1.74.6 Proceeds from stock options exercised
3.426.8Net Cash Provided by Financing Activities
32.631.8Effect of exchange rate changes on cash and cash equivalents
6.66.3Net change in cash and cash equivalents
58.4(7.2)Cash and cash equivalents at beginning of period
597.5604.3Cash and cash equivalents at end of period
$
55.9$
597.1Supplemental Cash Flow Information:Cash paid (received) during the period- Interest
$
31.1$
31.0 Income taxes, net of refunds
$
(8.4)$
(21.0)Hospira, Inc.Net Sales by Product Line(Unaudited)(dollars in millions)Three Months Ended March 31,20122011% Change at
Actual Currency
Rates% Change at
Constant Currency
Rates (1)Americas-- Specialty Injectable Pharmaceuticals
$
457.7$
511.3(10.5)%(10.1)% Medication Management
213.2196.08.8%9.1% Other Pharma
99.4101.6(2.2)%(2.1)%Total Americas770.3808.9(4.8)%(4.4)%Europe, Middle East & Africa-- Specialty Injectable Pharmaceuticals
76.268.511.2%15.6% Medication Management
30.833.8(8.9)%(5.3)% Other Pharma
20.917.718.1%21.5%Total Europe, Middle East & Africa
127.9120.0
'/>"/>
| SOURCE Hospira, Inc. Copyright©2010 PR Newswire. All rights reserved |